[wiggles_md]

Your link is to the patent application. If you check PAIR, you’ll see that only a small subset of the claims, amended, have received NOA. I would tend to disagree about the strength of their IP portfolio based on a cursory glance at the publicly available info, but I’d be curious to hear why you think differently.

[DrAwdeOccarim]

Ouch, I didn't look at PAIR. They lost all their delivery claims. I was impressed by their priority date, which pre-dates some of the competition, but it looks like they lost most of the key claims they'll need to fight off a lawsuit.

[johnramunas]

Hi Guys, Thanks for your interest! An update from Rejuvenation Technologies: The comment above is incorrect. Our claims were simply moved to a continuation patent, US 16/735,681, which has been granted, and our granted patents now cover all in vitro and in vivo applications of TERT mRNA-based telomere extension. If you'd like more info, please feel free to email [e-mail]. Thanks again! Best regards, John